argenx (ARGX) Highlights 2024 Strategic Priorities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
argenx Highlights 2024 Strategic Priorities
January 8, 2024 1:00 AM ESTReported $1.2 billion in preliminary* full-year 2023 global net product sales
Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024
Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN
Data from six Phase 2 proof-of-concept trials expected by end of 2024
Nominated four new pipeline candidates with IND filings expected by end of 2025
January 8, 2024, 7:00 AM CET
... More